Compare WEAV & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | RGNX |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 418.1M |
| IPO Year | 2021 | 2015 |
| Metric | WEAV | RGNX |
|---|---|---|
| Price | $4.75 | $8.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $11.00 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 1.7M | 791.9K |
| Earning Date | 05-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,024,000.00 | $10,393,000.00 |
| Revenue This Year | $17.20 | $50.05 |
| Revenue Next Year | $13.74 | $23.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.99 | ★ 126.48 |
| 52 Week Low | $4.60 | $5.04 |
| 52 Week High | $12.17 | $16.19 |
| Indicator | WEAV | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 41.72 |
| Support Level | N/A | $7.83 |
| Resistance Level | $7.31 | $9.28 |
| Average True Range (ATR) | 0.26 | 0.51 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 15.18 | 13.64 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.